anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis-induced neuroinflammation is significantly associated with sepsis-related brain dysfunction. Remimazolam is a novel ultra-short-acting benzodiazepine anesthetic with multiple organ protective effects. However, it is unknown whether remimazolam can ameliorate LPS-induced brain impairment. In this study, Lipopolysaccharide (5 mg/kg, LPS) severely impaired Sprague-Dawley rats spatial learning ability, memory, and cognitive function. However, remimazolam treatment showed a protective effect on LPS-induced cognitive dysfunction. Remimazolam partly reversed LPS-induced splenomegaly, decreased serum cytokine expression, suppressed hippocampal M1 microglial activation, and mitigated oxidative stress injury and neuroinflammation. Electroacupuncture (EA) or PNU282987 treatment improved LPS-induced cognitive dysfunction and also significantly inhibited neuroinflammation and systemic inflammation. However, MLA, ML385, or subdiaphragmatic vagus nerve (SDV) treatment abolished the protective effects of remimazolam. Further mechanistic studies showed that remimazolam induces protective effects by activating subdiaphragmatic vagus nerve target α7nAChR-mediated Nrf2/HO-1 signaling pathway. These results demonstrate that remimazolam can up-regulate α7nAChR, Cyto-Nrf2, HO-1, and cognitive-related (CREB, BDNF, PSD95) protein expressions, suppress M1 microglia, ameliorate neuroinflammation or systemic inflammation, and reverse cognitive dysfunction. Therefore, this study provides insight into a new therapeutic target for the treatment of sepsis-induced cerebral dysfunction.
Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve - a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.
Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
While school-aged children in low- and middle-income countries remain highly exposed to acute infections, programs targeting this age group remain limited in scale and scope. In this study, we evaluate the impact of a new and comprehensive primary school-based health intervention program on student health outcomes and academic performance in Lusaka, Zambia. The intervention involved the training of teachers to become school health workers and the provision of vitamin A supplementation and deworming medication on a bi-annual basis. Teachers in intervention schools were trained to deliver health lessons and to refer sick students to care. This study is designed as a prospective matched control study. Students from the seven intervention schools are matched with students from control schools.
Despite the importance of dysarthria intervention in post-stroke rehabilitation, further research in this area remains underexplored. This study builds on previous research on the use of smartphone-based dysarthria interventions based on motor learning principles, such as repetitive training and feedback and neuroplasticity through repetition, motivation, and reward. The treatment duration of 1h, 5 times a week for 4 weeks, is consistent with previous behavioral interventions for post-stroke dysarthria. This study aimed to determine whether the condition of patients with stroke can be improved through the use of smartphone-based interventions. This is a single-center, investigator-blinded, randomized, crossover effectiveness study. In this study, both the objective and subjective measurements will be performed three times: at baseline, post-phase 1 study (week 4), and post-phase 2 study (week 8). The study includes three intervention cycles, and for each research cycle, 12 subjects will be recruited to participate (6 per each group × 3 cycles).
Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel or transplant donor-derived EBV- CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
This is a randomized controlled trial to evaluate the effect of a mobile application system using the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to improve patients' participation in symptom management during cancer treatment. Breast, lung, head and neck, esophagus, and gynecologic cancer patients who will begin new lines of chemotherapy or radiation therapy will be randomly assigned into the intervention and control groups (2:1 ratio). The intervention group will have the mobile application installed on their smart phones which they could record symptoms and adverse events due to cancer treatments using the pre-specified PRO-CTCAE questions for different types of cancer. The control group will have usual care. Primary endpoint is patients' participation/engagement of reporting symptoms and it will be evaluated at 8 weeks after the intervention using a questionnaire developed by the research team. Secondary end points are unexpected hospital visits during treatment during 8 weeks after the beginning of the treatment and quality of life at 8 weeks after the intervention.
1: \rbr\Interwoven\NRPortbl\DCC\RBR\14757173_l.docx-9 06/2017 The present invention relates to the use of a VEGF antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a VEGF antagonist for use in a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops. The invention further provides the use of a VEGF antagonist in the manufacture of a medicament for treating a child having a chorioretinal neovascular or permeability disorder. WO 2015/004616 PCT/IB2014/062978 Figure 1 0,3 0,2 0, 1 0,2 0.05 0.1 .2 05 Ratio of candidate Cmax and IC50
To provide methods or systems for treatment with or monitoring the use of a respiratory pressure therapy device.SOLUTION: The device may be for a respiratory disorder. A processor of a server communicating with the therapy device analyzes data relating to respiratory therapy delivered by the device and generates data representing a prediction, such as compliance predictions, about progress of the therapy on the basis of the analysis. The processor may select an action to improve the therapy on the basis of data representing the prediction. The processor may take or prompt the selected action to improve the therapy. In some cases, the processor analyzes usage data concerning a period of days with the therapy device and generates compliance prediction indicators on the basis of the analysis. The indicators indicate whether compliance will be likely. The processor may recommend an engagement action to improve compliance on the basis of evaluation of the indicators.SELECTED DRAWING: Figure 7a
Subjects will be scheduled for first apheresis collection on study Day 1. All subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous (SC) injection 4 to 5 days prior to the second apheresis collection. The study day for N-803 administration will be determined based on the planned date of the second apheresis collection.
BACKGROUND: Sitting is known to be bad for your cardiovascular health. We furthermore hypothesized that sitting posture will reduce perfusion of the foot and increase edema, possibly predisposing to disease like osteochondritis.
METHODS: We included 27 healthy volunteers and performed MRI measurements including arterial spin labelling (ASL) and intravoxel incoherent motion (IVIM) perfusion as well as short tau inversion recovery (STIR) edema measurement and 3D volumetry. After randomization, the elevation of one foot during the day was used as an intervention.
RESULTS: Intra- and interrater variability was 1-6%. ASL perfusion measurement was hindered by artifacts. IVIM perfusion showed no significant changes during supine measurements. Volumetry could demonstrate a highly significant (p = 0.00005) volume increase, while the intervention led to a significant (p = 0.0076) volume decrease during the day. However, the water content in STIR remained unchanged and the normalized (quotient bone/muscle) edema was reduced on the control side (p = 0.006) and increased on the intervention side (p = 0.01).
CONCLUSIONS: Sitting all day leads to swelling of the healthy foot. Compensation in healthy subjects seems to prevent lasting perfusion changes or edema evolution in the bone despite an increase of muscle signal and volume increase. Thus, the etiology of osteochondritis needs further studies.
Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease in newborns, which severely influences the health of infants and lacks effective clinical treatment strategies. The pathogenesis of BPD is correlated to enhanced inflammation and activated oxidative stress (OS). The application of antioxidants and anti-inflammatory treatment could be hot spots for BPD treatment. Nesfatin-1, a peptide with a suppressive property against inflammation, was tested herein for its potential therapeutic value in BPD. Neonatal SD rats were stimulated with hyperoxia, followed by being intraperitoneally administered with 20 μg/kg/day Nesfatin-1 for 2 weeks. Decreased RAC value in lung tissues, increased wet weight/dry weight (W/D) pulmonary ratio and bronchoalveolar lavage fluid (BALF) proteins, elevated cytokine release in BALF, increased malondialdehyde (MDA) content, and declined superoxide dismutase (SOD) activity were observed in BPD rats, all of which were sharply mitigated by Nesfatin-1. Rat epithelial type II cells (AECIIs) were handled with hyperoxia, and then cultured with 1 and 10 nM Nesfatin-1. Reduced cell viability, elevated lactate dehydrogenase production, elevated cytokine secretion, elevated MDA content, and decreased SOD activity were observed in hyperoxia-handled AECIIs, all of which were markedly alleviated by Nesfatin-1. Furthermore, activated nuclear factor-κB (NF-κB) signaling observed in both BPD rats and hyperoxia-handled AECIIs were notably repressed by Nesfatin-1. Collectively, Nesfatin-1 alleviated hyperoxia-triggered BPD by repressing inflammation and OS via the NF-κB signaling pathway.
Despite increasing availability of Nexplanon in the United States, only limited resesarch exists on Nexplanon use among adolescents, particularly nulliparous adolescents. A Cochrane systematic review of long-acting contraception use among adolescents in 2017 identified only four studies that had specifically assessed implant use and continuation among adolescents \[1\]. Of these, the majority of studies assessed use postpartum \[1\]. The majority of research on adolescent attitudes around and barriers to long-acting reversible contraception has been conducted on intrauterine devices, rather than implants, and further research is needed to understand decision-making and behaviors around implant use \[2\]. Additionally, no studies have assessed differences in adolescent decision-making by age. While adolescence is considered ages 10-24 \[3\], this period is one of substantial change, physically, mentally, and in stages of life. Contraceptive use can be influenced by all of these \[4\] and understanding differences in stages of adolescence could result in meaningful differences in counseling and support approaches.

The purpose of this study is to compare Nexplanon decision-making, uptake, satisfaction and contraceptive outcomes (continuation, switching, discontinuation) over a 12-month period among adolescents ages 15-18 to adolescents ages 19-24, living in Utah. Data from this study will provide valuable information for clinical and public health offerings, counseling and support for Nexplanon use across stages of adolescence.
PURPOSE:The titled pharmaceutical preparation not precipitating an active ingredient, not irritating oral cavity, having improved medicinal effect, obtained by blending a nonsteroid anti-inflammatory analgesic with a water-soluble high polymer compound of a gelatinizing agent, and, if necessary, a water-soluble basic substance, to give a gel component with specific pH. CONSTITUTION:A nonsteroid anti-inflammatory analgesic (e.g., diclofenac sodium, ketoprofen, etc.) of an active ingredient is blended with a water-soluble high polymer compound (e.g., MC, CMC-Na, etc.) of a gelatinizing agent, and, if necessary, a water-soluble basic substance, to give an anti-inflammatory agnalgesic gel for oral cavity of a gel component with 6-8pH. Triethanolamine, or alkali salt of hydroxide is preferable as the water-soluble basic substance, and its amount is an amount enought to dissolve water-soluble anti-inflammatory analgesic such as ketoprofen, fentizac, etc. The active ingredient will not precipitate even in the absence of an alcohol component, the gel has good spreadability to the mucosa and good medicinal effect, having no irritation in oral cavity.
FIELD: organic chemistry, chemical technology, biochemistry. SUBSTANCE: invention discloses the novel stereoisomeric indole compounds of the formula (I)   where Y, X, R 1 ,R 2  and R are characterized in description, method of their synthesis and using. The above indicated compounds can be synthesized by condensation of tryptophan with stereoisomeric α-amino acid or carboxylic acid to yield amide form and the following cyclization of amide form to form oxazolic ring. Compounds show physiological activity, for example, an inhibitory effect against lipid peroxidation and can be used as inhibitors of lipid peroxidation comprising the indicated active component. EFFECT: improved method of synthesis, valuable biochemical properties. 7 cl, 10 dwg, 2 tbl, 8 ex
The invention provides a traditional Chinese medicine medicament for treating headache, and relates to the technical field of Chinese herbal medicines. The formula comprises the following components in parts by weight: 5-15 parts of ligusticum wallichii, 5-15 parts of radix angelicae, 10-20 parts of folium mori, 10-20 parts of chrysanthemum, 10-20 parts of radices ligustici sinensis, 10-25 parts of acorus calamus root, 10-25 parts of cocklebur fruit, 3-8 parts of asarum, 1-5 parts of radices sileris, 2-5 parts of sichuan paeonia albiflora, 1-3 parts of gastrodia elata, 5-8 parts of salviae miltiorrhizae, 3-4 parts of rhizoma typhonii and 1-2 parts of monkshood. The ligusticum wallichii, the radix angelicae, the folium mori, the chrysanthemum, the radices ligustici sinensis, the acorus calamus root and the cocklebur fruit are boiled at a certain ratio and taken warmly. By adopting the traditional Chinese medicine medicament, the headache can be effectively treated. In addition, various side effects and dependence caused by long-term use of the medicament for treating the disease frequently can be avoided, and the materials are drawn from common foods in daily life, and are low in cost. The slight illness can be removed in the process of enjoying delicious foods, and the effects of injections, pills or even operations are avoided.
Pharmacogenomics is the study of how a patient's unique DNA may interact with medications that the patient currently takes or may take in the future. DNA may change how a patient reacts to a medication, such as changing how well it works or the side effects. Knowing a patient's DNA profile may help healthcare professionals select the best medication treatment plan to use. This could include selecting the best medication to give or the medication strength that will work best for the patient. Currently, there is no standard that helps healthcare professionals decide to order a pharmacogenomics test that includes multiple genes. The investigators of this study think that having these DNA results in the medical record for participants who are at least 65 years old and are taking 5 or more medications will result in better health since healthcare professionals may use these results for treatment planning. Knowing if this is true will help healthcare professionals decide if ordering this test will improve patient health.

This study seeks to recruit participants for a pharmacogenomic study who visit at Geisinger 65 Forward locations. Patients who meet the study requirements and consent to be enrolled in this study will be randomly put into a group that receives this pharmacogenomics test or a group that does not receive it. There is a 50% chance of being put in the group that receives this pharmacogenomics test. The investigators will follow all patients enrolled in this study as they visit with their healthcare providers in the future. Geisinger healthcare professionals will have access to the results of this test in the medical record.
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T- cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
The present invention relates to a method for suppressing the activity of the matrix metalloproteinases (MMPs) in the skin including the topical application of a composition, which has an effective ratio for the synergistic action related to the concentration of a hydroxamic acid, salt of the hydroxamic acid, and/or a complex thereof and the concentration of glycols, to the skin′s surface. According to partial embodiments of the present invention, the ratio of the weight percentage of the hydroxamic acid, salt of the hydroxamic acid, and/or the complex thereof with respect to the weight percentage of the glycols can be selected from a group including 1:1.4, 1:3, and 1:5 with respect to the weight of the total composition in an approximating manner. The present invention also relates to methods for preventing or reducing aging on the skin surface. The methods include the topical application of a composition, which has the effective ratio for the synergistic action related to the concentration of a hydroxamic acid, salt of the hydroxamic acid, and/or a complex thereof and the concentration of glycols, to the surface of a skin. The methods for increasing the enzymatic inhibition potential of the glycols include a step of coupling one or more glycols with the hydroxamic acid, salt of the hydroxamic acid, and/or a complex thereof in the amounts in accordance with the effective ratio for the synergistic action for forming a synergistic mixture. Enzymatic inhibition potential of the synergistic mixture is greater than the enzymatic inhibition potential of glycols or the hydroxamic in a standalone manner. The present invention also relates to anti-aging compositions for suppressing the activities of MMPs in the skin with the effective ratio of the concentration of the hydroxamic acid, salt of the hydroxamic acid, and/or a complex thereof and the concentration of glycols for the synergetic action within the above-described range. In partial embodiments of the present invention, the weight percentage ratio can be selected from a group including 1:1.4, 1:3, and 1:5 with respect to the weight of the total composition.
Store ZEGALOGUE in a refrigerator, 2°C to 8°C (36°F to 46°F). Keep away from the cooling element. Do not freeze.

ZEGALOGUE can be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 12 months. Record the date when the product was removed from the refrigerator in the space provided on the protective case. Do not return the product to the refrigerator after storing at room temperature. Store in the provided protective case and protect from light.

Discard ZEGALOGUE after the end of the 12-month period at room temperature storage, or after the expiration date stated on the product, whichever occurs first.

The inside of the gray cap on ZEGALOGUE autoinjector contains dry natural rubber (a derivative of latex).

The inside of the gray needle cover on ZEGALOGUE prefilled syringe contains dry natural rubber (a derivative of latex).